Screener
Veracyte VCYT Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Testing revenue | $135,091 | $107,309 |
| Product revenue | 3,679 | 3,580 |
| Biopharmaceutical and other revenue | 301 | 3,584 |
| Total revenue | 139,071 | 114,473 |
| Cost of revenue: | ||
| Cost of testing revenue | 33,306 | 28,260 |
| Cost of product revenue | 1,891 | 1,422 |
| Cost of biopharmaceutical and other revenue | 8 | 2,698 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's total revenue?
- Veracyte (VCYT) reported total revenue of $139.07M in Q1 2026.
- How has Veracyte's total revenue changed year-over-year?
- Veracyte's total revenue increased by 21.5% year-over-year, from $114.47M to $139.07M.
- What is the long-term trend for Veracyte's total revenue?
- Over 4 years (2021 to 2025), Veracyte's total revenue has grown at a 23.9% compound annual growth rate (CAGR), from $219.51M to $517.15M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Veracyte's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude